The independent platform for news, articles and advice for professionals in laboratory medicine

PathAI launches AI powered HER2 scoring algorithm

PathAI has announced the availability of AIM-HER2 Breast Cancer for research use by clinical laboratories, researchers, and drug developers. AIM-HER2 Breast Cancer delivers automated digital HER2 scoring and is the market’s first algorithm to use additive multiple instance learning (aMIL) heatmaps to visualise the slide features driving the algorithm’s predicted score.

AIM-HER2 will be available to biopharma researchers and clinical research laboratory pathologists on PathAI’s AISight digital pathology platform in both the clinical research and clinical trial setting.

“HER2 IHC assays have provided immense impact to patients by allowing for a widely available test to establish drug eligibility,” said Mike Montalto, Chief Scientific Officer at PathAI. “With AIM-HER2 Breast Cancer, we at PathAI sought to build upon the success of HER2 testing by assisting pathologists in their ability to more confidently score HER2, especially in borderline cases that can be the most challenging and time consuming to review. We also look forward to partnering with drug developers who may be interested in enhancing the scoring of the more recently described HER2 low assay as an important emerging patient population.”

In addition to predicting slide-level HER2 score, AIM-HER2 Breast Cancer’s visualisations on AISight utilise additive multiple instance learning (aMIL) heatmaps to deliver a more interpretable and explainable prediction, diminishing the ‘black box’ challenges typically associated with understanding how AI predictions are made. “Our interpretable heatmaps are critical to driving utilisation and adoption of AI – because it’s not about blind trust,” said Eric Walk, Chief Medical Officer at PathAI. “The results can be interpreted, explained – and confirmed – by humans. It also streamlines workflow as it allows pathologists to home in on specific features to confirm the algorithm score and output vs. needing to analyse the entire slide.”

AIM-HER2 Breast Cancer was developed using 157,000 tissue annotations and consensus scores on a dataset of over 4,000 slides (collected from more than 65 expert breast pathologists). In addition to slide-level HER2 scoring, AIM-HER2 Breast Cancer quantifies invasive carcinoma and provides a comprehensive analysis of the entire WSI without necessitating manual selection of the region of interest (ROI).

 

Upcoming Events

Digital Pathology & AI Congress: Europe

The Intercontinental London Hotel, The O2, London SE10 0TW
7-8 December

POCT Innovators: The Power to Disrupt Series

Cloth Hall Court, Leeds. UK
20 March, 2024

USCAP 113th Annual Meeting

Baltimore Convention Center, Baltimore, Maryland, USA
23-28 March, 2024

ECCMID 2024 - European Congress of Clinical Microbiology and Infectious Diseases

Fira Gran Via, 08038 Barcelona, Spain
27-30 April 2024

British Society for Microbial Technology Annual Microbiology Conference

Royal Air Force Museum, Hendon, London
2 May 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Upcoming Events

Digital Pathology & AI Congress: Europe

The Intercontinental London Hotel, The O2, London SE10 0TW
7-8 December

POCT Innovators: The Power to Disrupt Series

Cloth Hall Court, Leeds. UK
20 March, 2024

USCAP 113th Annual Meeting

Baltimore Convention Center, Baltimore, Maryland, USA
23-28 March, 2024

ECCMID 2024 - European Congress of Clinical Microbiology and Infectious Diseases

Fira Gran Via, 08038 Barcelona, Spain
27-30 April 2024

British Society for Microbial Technology Annual Microbiology Conference

Royal Air Force Museum, Hendon, London
2 May 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999 Fax: 01892 616177
www.step-communications.com
© 2023 Step Communications Ltd. Registered in England. Registration Number 3893025